IDH2 and cholangiocarcinoma: We then selected the chondrosarcoma cell line SW1353, which harbors an IDH2 mutation (R172S/+), as well as the cholangiocarcinoma cell line RBE, which harbors an IDH1 mutation (R132S/+) for combination ATR and PARP inhibitor studies.